Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis | Zendy

Nathan Liu | Zendy; Robert Chapman | Zendy; Yiyang Lin | Zendy; Jonas Mmesi | Zendy; Andrew Bentham | Zendy; Matthew Tyreman | Zendy; Sonya Abraham | Zendy; Molly M. Stevens | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis

Author(s) -

Nathan Liu,

Robert Chapman,

Yiyang Lin,

Jonas Mmesi,

Andrew Bentham,

Matthew Tyreman,

Sonya Abraham,

Molly M. Stevens

Publication year - 2016

Publication title -

nanoscale

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.038

H-Index - 224

eISSN - 2040-3372

pISSN - 2040-3364

DOI - 10.1039/c5nr08423g

Subject(s) - rheumatoid arthritis , medicine , serology , phospholipase a2 , point of care , point of care testing , psoriatic arthritis , antibody , immunology , gastroenterology , pathology , chemistry , biochemistry , enzyme

Secretory phospholipase A2 group IIA (sPLA2-IIA) was examined as a point of care marker for determining disease activity in rheumatoid (RA) and psoriatic (PsA) arthritis. Serum concentration and activity of sPLA2-IIA were measured using in-house antibodies and a novel point of care lateral flow device assay in patients diagnosed with varying severities of RA (n = 30) and PsA (n = 25) and found to correlate strongly with C-reactive protein (CRP). Levels of all markers were elevated in patients with active RA over those with inactive RA as well as both active and inactive PsA, indicating that sPLA2-IIA can be used as an analogue to CRP for RA diagnosis at point of care.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research